USANA Health Sciences (USNA) Tops Q4 EPS by 35c, offers guidance

USANA Health Sciences (NYSE: USNA) reported Q4 EPS of $0.87, $0.35 better than the analyst estimate of $0.52. Revenue for the quarter came in at $221 million versus the consensus estimate of $212.84 million.

GUIDANCE:

USANA Health Sciences sees FY2024 EPS of $2.40-$3.00, versus the consensus of $2.94. USANA Health Sciences sees FY2024 revenue of $850-920 million, versus the consensus of $912.3 million.

For earnings history and earnings-related data on USANA Health Sciences (USNA) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Redburn upgrades Southwest, stays bullish on Delta and United
• Amneal gets FDA approval for lanreotide injection, launches immediately